Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Sell Genzyme s SAGE Technology

NEW YORK, Oct 10 – Genzyme Moloecular Oncology said Tuesday that Invitrogen had licensed the exclusive rights to sell its Serial Analysis of Gene Expression technology in standardized reagent kits.

Under the terms of the agreement, Genzyme Molecular Oncology of Framingham, Mass., will receive an upfront payment and royalties on the sale of each SAGE kit. The agreement will also enable Invitrogen to distribute Genzyme Molecular Oncology's proprietary bioinformatics software for analysis of SAGE results.

Recently, a public gene expression database repository for SAGE data (SAGEmap) was produced through the US National Institute of Health's Cancer Genome Anatomy Project and is now capable of accepting submissions of SAGE sequence data from any source. The database currently contains over two million SAGE tags.

In addition to the agreement with San Diego-based Invitrogen, Genzyme has signed SAGE agreements with pharmaceutical and biotechnology companies including Celera, Pfizer, Bayer, Novartis Agricultural Discovery Institute, Affymetrix, Curis, Memorec, and Compugen.

All SAGE users are able to access the public database of SAGE information as well as make comparisons with the proprietary SAGE data available on Compugen's LabOnWeb and from Celera.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.